Independent Franchise Partners LLP Buys 2,456,451 Shares of Solventum Corporation $SOLV

Independent Franchise Partners LLP lifted its stake in shares of Solventum Corporation (NYSE:SOLV) by 19.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,355,691 shares of the company’s stock after purchasing an additional 2,456,451 shares during the period. Solventum makes up about 7.7% of Independent Franchise Partners LLP’s investment portfolio, making the stock its biggest position. Independent Franchise Partners LLP owned approximately 0.09% of Solventum worth $1,216,785,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of SOLV. Measured Wealth Private Client Group LLC acquired a new position in Solventum in the third quarter valued at approximately $25,000. Hilltop National Bank lifted its holdings in Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the period. JNBA Financial Advisors lifted its holdings in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares during the period. CYBER HORNET ETFs LLC acquired a new position in Solventum in the second quarter valued at approximately $28,000. Finally, City State Bank lifted its holdings in Solventum by 166.7% in the fourth quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after buying an additional 240 shares during the period.

Analyst Upgrades and Downgrades

SOLV has been the topic of several analyst reports. Stifel Nicolaus cut their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Wedbush initiated coverage on shares of Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price on the stock. KeyCorp increased their target price on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Rothschild & Co Redburn initiated coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $84.25.

Solventum Stock Performance

Shares of SOLV stock opened at $74.48 on Thursday. The stock has a market cap of $12.90 billion, a P/E ratio of 9.13, a P/E/G ratio of 1.18 and a beta of 0.69. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The company has a fifty day moving average price of $73.25 and a two-hundred day moving average price of $75.00. Solventum Corporation has a one year low of $62.38 and a one year high of $88.20.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.